Skip to content
Triangle logo TriangleGet started
← Study library

NCT03267680 · REGISTRY CONDITION SEARCH

IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
TERMINATED
Registry last update
2025-04-13

This randomized phase II trial studies how well an IRX-2 Regimen works in treating women with cervical squamous intraepithelial neoplasia 3 or squamous vulvar intraepithelial neoplasia 3. The IRX-2 Regimen consists of a single dose of cyclophosphamide, followed by 21 days of indomethacin, zinc-containing multivitamins, and omeprazole. IRX-2, a human cell-derived biologic with multiple active cytokine components, may act as an immune booster to stimulate the immune system. Giving cyclophosphamide and IRX-2 may work better at treating cervical squamous intraepithelial neoplasia or squamous vulvar intraepithelial neoplasia.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Pathologic Response

→

outcome · POSTED

Incidence of Adverse Events of IRX-2 Administration

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Histologically confirmed squamous CIN 3, or VIN 3 (usual type only) * The subject is either surgically sterile, postmenopausal, or agrees to practice an effective method of birth control as determined by the investigator (to be continued throughout the study period), except that subjects with CIN 3 are not permitted to use a cervical cap or diaphragm for contraception * White blood cell \> 2,500/ mcL (\> 2.5 x 10\^9/L) * Absolute neutrophil count \> 1,000/ microliter (\> 1 x 10\^9/L) * Platelet count \> 75,000/ mcL (\> 75 x 10\^9/L) * Hemoglobin \>= 8 g/dL (\>= 80 g/L) (subjects who have received a transfusion or erythropoietin up to one week prior to receiving the first dose of cyclophosphamide are eligible for the study) * International normalized ration (INR) or prothrombin time (PT) \< 1.5 x ULN (upper limit of normal) * Activated partial thromboplastin time (aPTT) \< 1.5 x ULN * Serum creatinine \< 1.5 x ULN * Total bilirubin \< 2.0 x ULN unless thought to be related to inherited bilirubin conjugation disorder (ie Gilbert?s disease) * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 2.5 x ULN * The subject is geographically accessible for ongoing follow-up and is committed to comply with the designated visits * The subject is capable of understanding and complying with the protocol and has signed the enrollment informed consent form at screening Exclusion Criteria: * For subjects with cervical dysplasia: evidence of atypical glandular cells or adenocarcinoma in situ (ACIS) based on cervical cytology, colposcopy or biopsy * For subjects with either cervical or vulvar squamous dysplasia: evidence of microinvasive squamous carcinoma based on cytology, colposcopy or biopsy * Pregnancy or lactation * Allergy to ciprofloxacin or other quinolones (because ciprofloxacin is used in preparation of IRX-2) * Allergy to indomethacin (a necessary component of the regimen) or to acetylsalicylic acid (aspirin) due to likely allergy cross-reaction * Aldara (imiquimod) for the topical treatment of lower genital tract warts or dysplasia within 3 months of study enrollment * Known to be positive for human immunodeficiency virus-1 (HIV-1) antibody, human immunodeficiency virus-2 (HIV-2) antibody, hepatitis B surface antigen, or hepatitis C virus antibody * Known to have other immunodeficiency diseases, including cellular immunodeficiencies, hypogammaglobulinemia, or dysgammaglobulinemia * Immunotherapy (eg, interferons, tumor necrosis factor, interleukins) or biological response modifiers (granulocyte-macrophage colony-stimulating factor, granulocyte colony-stimulating factor, macrophage colony-stimulating factor) or any investigational drug within 3 months of study enrollment * Concurrent treatment with systemic corticosteroids at a dose of \>= 5 mg/day of prednisone (or equivalent) * Subjects should not take aspirin (except for low-dose aspirin as prescribed for vascular disease) or other non-prescribed, non-steroidal anti-inflammatory agents from randomization to surgery * An infectious process or any other significant illness such as an autoimmune disease or advanced age that in the opinion of the investigator would compromise the subject?s ability to mount an immune response * Impaired hepatic, renal or hematological function, evidenced by: * Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin \>= 2 times upper limit of normal (ULN), * Serum creatinine \>= 2 times ULN, or * Clinically significant active cardiovascular disease, including a history of myocardial infarction within the past 6 months, heart failure as defined by New York Heart Association classes III or IV, and/or blood pressure greater than 160/90 mm Hg (1 repeat measure allowed no more than 5 minutes after the first measurement) * History of severe allergic reaction to insect bites or stings, or to any biologic pharmaceutical product, including compounds similar to the test article * Any medical contraindications, allergies or previous therapy that would preclude treatment with the components of the IRX-2 regimen, i.e., cyclophosphamide, indomethacin, zinc-containing multivitamins or omeprazole * Donation or loss of \> 450 mL of blood or plasma within 30 days of randomization
healthy Volunteers
false
minimum Age
25 Years
sex
FEMALE
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive cyclophosphamide IV on day 1 and IRX-2 via submucosal injections in the cervix or SC for vulvar lesions on days 4-7. Patients also receive indomethacin PO TID, zinc-containing multivitamins PO QD and omeprazole PO on days 1-21. Treatment repeats every 6 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Beginning week 25, patients undergo surgical resection.
    intervention Names
    1. Drug: Cyclophosphamide
    2. Drug: Indomethacin
    3. Biological: IRX-2
    4. Other: Laboratory Biomarker Analysis
    5. Dietary Supplement: Multivitamin
    6. Drug: Omeprazole
    7. Procedure: Therapeutic Conventional Surgery
    label
    Arm I (IRX-2)
    type
    EXPERIMENTAL
  2. description
    Patients receive cyclophosphamide IV on day 1 and placebo via submucosal injections in the cervix or SC for vulvar lesions on days 4-7. Patients also receive indomethacin PO TID, zinc-containing multivitamins PO QD and omeprazole PO on days 1-21. Treatment repeats every 6 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Beginning week 25, patients undergo surgical resection.
    intervention Names
    1. Drug: Cyclophosphamide
    2. Drug: Indomethacin
    3. Other: Laboratory Biomarker Analysis
    4. Dietary Supplement: Multivitamin
    5. Drug: Omeprazole
    6. Other: Placebo
    7. Procedure: Therapeutic Conventional Surgery
    label
    Arm II (placebo)
    type
    ACTIVE_COMPARATOR
interventions
  1. arm Group Labels
    1. Arm I (IRX-2)
    2. Arm II (placebo)
    description
    Given IV
    name
    Cyclophosphamide
    type
    DRUG
  2. arm Group Labels
    1. Arm I (IRX-2)
    2. Arm II (placebo)
    description
    Given PO
    name
    Indomethacin
    type
    DRUG
  3. arm Group Labels
    1. Arm I (IRX-2)
    description
    Given via submucosal injection or SC
    name
    IRX-2
    type
    BIOLOGICAL
  4. arm Group Labels
    1. Arm I (IRX-2)
    2. Arm II (placebo)
    description
    Correlative studies
    name
    Laboratory Biomarker Analysis
    type
    OTHER
  5. arm Group Labels
    1. Arm I (IRX-2)
    2. Arm II (placebo)
    description
    Given zinc-containing multivitamin PO
    name
    Multivitamin
    other Names
    1. Geritol
    2. Vitamin Supplements (NOS)
    type
    DIETARY_SUPPLEMENT
  6. arm Group Labels
    1. Arm I (IRX-2)
    2. Arm II (placebo)
    description
    Given PO
    name
    Omeprazole
    type
    DRUG
  7. arm Group Labels
    1. Arm II (placebo)
    description
    Given via submucosal injections or SC
    name
    Placebo
    other Names
    1. placebo therapy
    2. sham therapy
    type
    OTHER
  8. arm Group Labels
    1. Arm I (IRX-2)
    2. Arm II (placebo)
    description
    Undergo surgical resection
    name
    Therapeutic Conventional Surgery
    type
    PROCEDURE
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
DOUBLE
who Masked
  1. PARTICIPANT
  2. INVESTIGATOR
primary Purpose
TREATMENT
Enrollment
count
10
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Complete Response (CR) is defined as absence of intraepithelial neoplasia, Partial Response (PR) is defined as a lower grade of dysplasia than present at baseline (for example, grade 3 decreasing to grade 1).
    measure
    Pathologic Response
    time Frame
    Week 25
secondary Outcomes
  1. description
    Will be assessed by the incidence and severity of adverse events, serious adverse events, as classified and graded according to the current version of the Common Terminology Criteria for Adverse Events version 4.
    measure
    Incidence of Adverse Events of IRX-2 Administration
    time Frame
    Up to 30 months
Full study description
brief Summary
This randomized phase II trial studies how well an IRX-2 Regimen works in treating women with cervical squamous intraepithelial neoplasia 3 or squamous vulvar intraepithelial neoplasia 3. The IRX-2 Regimen consists of a single dose of cyclophosphamide, followed by 21 days of indomethacin, zinc-containing multivitamins, and omeprazole. IRX-2, a human cell-derived biologic with multiple active cytokine components, may act as an immune booster to stimulate the immune system. Giving cyclophosphamide and IRX-2 may work better at treating cervical squamous intraepithelial neoplasia or squamous vulvar intraepithelial neoplasia.
detailed Description
PRIMARY OBJECTIVES: I. To compare the proportion of subjects who achieve a pathologic complete response (CR) or partial response (PR) in regimen 1 versus regimen 2 at week 25, based on the resected surgical specimen. SECONDARY OBJECTIVES: I. To evaluate the toxicity and feasibility of administration of IRX-2 in subjects with confirmed cervical intraepithelial neoplasia (CIN) 3 or vulvar intraepithelial neoplasia (VIN) 3. II. To evaluate multiple parameters to assess the activity of the IRX-2 regimen for the treatment of CIN 3 or VIN 3: the occurrence of clinical CRs or PRs at weeks 6, 13 and 25. III. To evaluate multiple parameters to assess the activity of the IRX-2 regimen for the treatment of CIN 3 or VIN 3: frequency of elimination of human papillomavirus (HPV) in cervical or vulvar tissue using a commercial HPV genotyping assay and viral load determination by quantitative polymerase chain reaction (PCR). IV. To evaluate multiple parameters to assess the activity of the IRX-2 regimen for the treatment of CIN 3 or VIN 3: analysis of the immune infiltrates in the resected surgical specimens. V. To evaluate multiple parameters to assess the activity of the IRX-2 regimen for the treatment of CIN 3 or VIN 3: immunophenotypic analysis of peripheral blood lymphocytes. VI. To evaluate multiple parameters to assess the activity of the IRX-2 regimen for the treatment of CIN 3 or VIN 3: frequency of serum antibodies to HPV E6, E7 and L1 proteins by enzyme-linked immunosorbent assay (ELISA). VII. To evaluate multiple parameters to assess the activity of the IRX-2 regimen for the treatment of CIN 3 or VIN 3: ribonucleic acid (RNA) expression profiling of immune-inflammatory markers from post-treatment resected surgical specimens. OUTLINE: Patients are randomized to 1 of 2 arms. Arm I: Patients receive cyclophosphamide intravenously (IV) on day 1 and IRX-2 via submucosal injections in the cervix or subcutaneously (SC) for vulvar lesions on days 4-7. Patients also receive indomethacin orally (PO) three times daily (TID), zinc-containing multivitamins (PO) once daily (QD) and omeprazole orally (PO) on days 1-21. Arm II: Patients receive cyclophosphamide IV on day 1 and placebo via submucosal injections in the cervix or SC for vulvar lesions on days 4-7. Patients also receive indomethacin PO TID, zinc-containing multivitamins PO QD and omeprazole PO on days 1-21. In both arms, treatment repeats every 6 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Beginning week 25, patients undergo surgical resection. After completion of study treatment, patients are followed up at 1-8 weeks after surgery.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-2648f173da439a26efe7
      requested nct id
      NCT03267680
      primary nct id
      NCT03267680
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      9c84fe83f9fcdb12f3a6bb624863442db2afcee53df61c38a03e4f013f7f76a1
      payload sha256
      7996a99f290a8d5772748608533287309cb211b3f96793f4689ddafc1f94452f
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-2648f173da439a26efe7
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT03267680
      occurrences
      1. context exact
        NCT03267680
        end
        11
        exact text
        NCT03267680
        start
        0
      offset unit
      unicode_code_points
      query cond
      Vulvar Cancer
      query disease state id
      ds-vulvar-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-vulvar-cancer-000.json
      source file sha256
      9c84fe83f9fcdb12f3a6bb624863442db2afcee53df61c38a03e4f013f7f76a1
      source json pointer
      /studies/18/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      a910b7aadfb98fd109728cbd39933171f9378a116d16d9a21f2cae3ecd6ce56b

    Preserved source evidence · Not medical advice